SCHEMBL9102928

SCHEMBL9102928

NC(=O)c1ccc2ccccn12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BAZ2B Q9UIF8 2/20 0.39
BAZ2A Q9UIF9 2/20 0.39
MAPT P10636 4/20 0.37
L3MBTL1 Q9Y468 3/20 0.37
TSHR P16473 2/20 0.37
CYP2C19 P33261 2/20 0.37
HSD17B10 Q99714 2/20 0.37
POLB P06746 1/20 0.37
CYP3A4 P08684 1/20 0.37
PARP1 P09874 1/20 0.37
RECQL P46063 1/20 0.37
BLM P54132 1/20 0.37
PMP22 Q01453 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
LMNA P02545 2/20 0.37
MAP3K14 Q99558 1/20 0.37
MAP2K3 P46734 2/20 0.36
PTGS1 P23219 1/20 0.35
PTGS2 P35354 1/20 0.35
KDM4E B2RXH2 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28070421 0.98 BAZ2B (0.38) BAZ2BBAZ2AMAPTL3MBTL1TSHR
SCHEMBL17894085 0.86 KDM4E (0.42) BAZ2BBAZ2AMAPTL3MBTL1TSHR
SCHEMBL1646369 0.85 L3MBTL1 (0.35) BAZ2BBAZ2AMAPTL3MBTL1CYP2C19
SCHEMBL31183044 0.79 PTGS2 (0.35) BAZ2BBAZ2AMAPTL3MBTL1CYP2C19
SCHEMBL6535007 0.79 ALDH1A1 (0.45) MAPTL3MBTL1CYP3A4TDP1KDM4E
SCHEMBL29206234 0.77 ALDH1A1 (0.41) BAZ2BBAZ2AMAPTL3MBTL1CYP2C19
SCHEMBL6248007 0.76 L3MBTL1 (0.40) BAZ2BBAZ2AMAPTL3MBTL1CYP2C19
SCHEMBL4617203 0.76 IRAK4 (0.39) MAPTL3MBTL1TSHRCYP2C19HSD17B10
SCHEMBL25515640 0.76 MAPT (0.48) MAPTL3MBTL1TSHRHSD17B10POLB
SCHEMBL25515348 0.76 PTPN1 (0.42) BAZ2BBAZ2AMAPTL3MBTL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12286429-B2 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives useful as a factor XIa inhibitors JANSSEN PHARMACEUTICA NV (BE) 2025-04-29 US disclosed
CN-117083282-A Tetracyclic heterocyclic compounds useful as HIV integrase inhibitors 默沙东有限责任公司 2023-11-17 CN disclosed
US-20230064443-A1 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide Derivatives Useful As a Factor XIa Inhibitors JANSSEN PHARMACEUTICA NV (BE) 2023-03-02 US disclosed
WO-2021115457-A9 PYRAZOLO[1,5-A]PYRIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 深圳众格生物科技有限公司 2022-05-19 WO disclosed
CN-112979645-B Preparation method of indolizine 3-position formamide derivative 广东药科大学 2022-04-19 CN disclosed
WO-2022063050-A1 PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2022-03-31 WO disclosed
CN-112979645-A Preparation method of indolizine 3-position formamide derivative 广东药科大学 2021-06-18 CN disclosed
CN-105658641-B Benzazole amide derivatives, its preparation method and its application in medicine 江苏恒瑞医药股份有限公司 2018-04-17 CN disclosed
CN-105658641-A Indole-amide derivative, preparation method therefor and application thereof in medicine 江苏恒瑞医药股份有限公司 2016-06-08 CN disclosed
CN-102548993-B Cyclic (aza)indolizinecarboxamides, their preparation and their use as pharmaceuticals SANOFI AVENTIS 2014-12-10 CN disclosed
EP-2459557-B1 CYCLIC (AZA)INDOLIZINECARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2013-09-18 EP disclosed
US-8415336-B2 Cyclic (aza)indolizinecarboxamides, their preparation and their use as pharmaceuticals SANOFI (FR) 2013-04-09 US disclosed
CN-102295644-B Method for synthesizing 1-halo-2-aryl indolizine compound UNIV TONGJI 2012-12-05 CN disclosed
US-20120232081-A1 CYCLIC (AZA)INDOLIZINECARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI (FR) 2012-09-13 US disclosed
CN-102548993-A Cyclic (aza)indolizinecarboxamides, their preparation and their use as pharmaceuticals SANOFI AVENTIS 2012-07-04 CN disclosed
EP-2459557-A1 CYCLIC (AZA)INDOLIZINECARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI (FR) 2012-06-06 EP disclosed
CN-102295644-A Method for synthesizing 1-halo-2-aryl indolizine compound 2011-12-28 CN disclosed
WO-1996021662-A1 THE USE OF HETEROCYCLIC COMPOUNDS AS ANTIOXIDANTS, RADICAL SCAVENGERS, Fe2+ COMPLEXING AGENTS, TISSUE- AND/OR NEUROPROTECTANTS RISE FRODE (NO) 1996-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12286429-B2 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives useful as a factor XIa inhibitors F11, F12, F13A1 BAZ2B 1734/4885BAZ2A 1248/4885MAPT 4701/4885
US-20230064443-A1 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide Derivatives Useful As a Factor XIa Inhibitors F11, F12, F13A1 BAZ2B 1631/4885BAZ2A 1156/4885MAPT 4640/4885
US-20120232081-A1 CYCLIC (AZA)INDOLIZINECARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS REN, ACE, PM20D2 BAZ2B 523/4885BAZ2A 340/4885MAPT 4407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.